Augmented Reality, Mixed Reality, Virtual Reality, and Extended Reality Applications in Personalized Oncology and Patient-Centered Cancer Care: A Narrative Review.

IF 2.1 4区 医学 Q4 ONCOLOGY
Malarkodi Velraj, Deepalakshmi Mani, Arun Kanniyappan Parthasarathy, Vijayakumar Murugesan, Kommu Pradeep, Surabhi Panneerselvam, Panneerselvam Theivendren
{"title":"Augmented Reality, Mixed Reality, Virtual Reality, and Extended Reality Applications in Personalized Oncology and Patient-Centered Cancer Care: A Narrative Review.","authors":"Malarkodi Velraj, Deepalakshmi Mani, Arun Kanniyappan Parthasarathy, Vijayakumar Murugesan, Kommu Pradeep, Surabhi Panneerselvam, Panneerselvam Theivendren","doi":"10.1111/ajco.70172","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Extended reality (XR) technologies, including augmented reality (AR), mixed reality (MR), and virtual reality (VR), are an appealing technology in clinical oncology. This narrative review evaluates the current evidence of XR applications throughout the cancer care continuum in terms of the clinical implementation, patient outcome, and the relevance of the practice to practicing clinical oncologists.</p><p><strong>Methods: </strong>A literature search on PubMed, Scopus, Web of Science, and Cochrane Library (January 2015-December 2025) was conducted at the right time to select the articles related to AR, VR, MR, XR, and cancer/oncology. Randomized controlled trials (RCTs), systematic reviews, meta-analyses, and clinical implementation studies were given priority.</p><p><strong>Results: </strong>VR contains the strongest evidence base in which 15 RCTs meta-analysis (n = 864) found large reductions in the level of anxiety related to chemotherapy (standardized mean difference [SMD] = -1.40) among adult patients with cancer and fatigue (SMD = -3.85). Cancer-related pain (SMD = -0.86, 95% CI: -1.89 to -0.85, p < 0.001) affected significantly VR interventions as well when implemented in 28 RCTs. In hepatic, glioma, and gastrointestinal tumor resection, AR-guided surgical navigation has been clinically workable, and prospective research has indicated that it is capable of better tumor localization. Depression (SMD = -1.86, p < 0.001) was also reduced. The 3D holographic visualization with the help of MR enables the treatment planning of the multidisciplinary type.</p><p><strong>Conclusions: </strong>The XR technologies possess immense potential in the field of personalized oncology. The sphere of VR-based supportive care intervention is clinically prepared, and still the uses of AR and MR in surgical oncology require confirmation of multicenter trials. Standardization of the protocols, cost-effectiveness studies and its integration into the clinical processes are yet to remain on the list of the top priorities.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajco.70172","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Extended reality (XR) technologies, including augmented reality (AR), mixed reality (MR), and virtual reality (VR), are an appealing technology in clinical oncology. This narrative review evaluates the current evidence of XR applications throughout the cancer care continuum in terms of the clinical implementation, patient outcome, and the relevance of the practice to practicing clinical oncologists.

Methods: A literature search on PubMed, Scopus, Web of Science, and Cochrane Library (January 2015-December 2025) was conducted at the right time to select the articles related to AR, VR, MR, XR, and cancer/oncology. Randomized controlled trials (RCTs), systematic reviews, meta-analyses, and clinical implementation studies were given priority.

Results: VR contains the strongest evidence base in which 15 RCTs meta-analysis (n = 864) found large reductions in the level of anxiety related to chemotherapy (standardized mean difference [SMD] = -1.40) among adult patients with cancer and fatigue (SMD = -3.85). Cancer-related pain (SMD = -0.86, 95% CI: -1.89 to -0.85, p < 0.001) affected significantly VR interventions as well when implemented in 28 RCTs. In hepatic, glioma, and gastrointestinal tumor resection, AR-guided surgical navigation has been clinically workable, and prospective research has indicated that it is capable of better tumor localization. Depression (SMD = -1.86, p < 0.001) was also reduced. The 3D holographic visualization with the help of MR enables the treatment planning of the multidisciplinary type.

Conclusions: The XR technologies possess immense potential in the field of personalized oncology. The sphere of VR-based supportive care intervention is clinically prepared, and still the uses of AR and MR in surgical oncology require confirmation of multicenter trials. Standardization of the protocols, cost-effectiveness studies and its integration into the clinical processes are yet to remain on the list of the top priorities.

增强现实、混合现实、虚拟现实和扩展现实在个性化肿瘤学和以患者为中心的癌症治疗中的应用:叙述综述。
背景:扩展现实(XR)技术,包括增强现实(AR)、混合现实(MR)和虚拟现实(VR),在临床肿瘤学中是一项很有吸引力的技术。本文从临床实施、患者预后和临床肿瘤学家实践的相关性等方面评估了目前在癌症治疗连续体中XR应用的证据。方法:在合适的时间检索PubMed、Scopus、Web of Science、Cochrane Library(2015年1月- 2025年12月)的文献,选择AR、VR、MR、XR和癌症/肿瘤学相关的文章。随机对照试验(rct)、系统评价、荟萃分析和临床实施研究被优先考虑。结果:VR包含了最有力的证据基础,其中15项rct荟萃分析(n = 864)发现,在患有癌症和疲劳的成年患者中,化疗相关的焦虑水平(标准化平均差[SMD] = -1.40)大幅降低(SMD = -3.85)。癌症相关疼痛(SMD = -0.86, 95% CI: -1.89 ~ -0.85, p)结论:XR技术在个性化肿瘤学领域具有巨大的潜力。基于vr的支持治疗干预领域在临床上已经准备好了,AR和MR在外科肿瘤学中的应用仍然需要多中心试验的确认。方案的标准化、成本效益研究及其与临床过程的整合仍然是最优先考虑的问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.40
自引率
0.00%
发文量
175
审稿时长
6-12 weeks
期刊介绍: Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书